Back to Newsroom

Corbus Pharmaceuticals Announces Presentation of Three Abstracts at the 2017 North American Cystic Fibrosis Conference

NORWOOD, MA — (Marketwired) — 09/25/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)(“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it will present three abstracts from its cystic fibrosis (“CF”) research and clinical development programs at the 2017 North American Cystic Fibrosis Conference(“NACFC”) being held November 2-4, in Indianapolis, IN.